Parsa Bastani

Parsa Bastani

Auto-generated profile, based on publicly available information

Parsa Bastani

Affiliation Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2023 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Open access
PBParsa Bastani
Parsa Bastani
AJAnna Jammeh
Anna Jammeh
FLFrederica Lamar
Frederica Lamar
JMJason H. Malenfant
Jason H. Malenfant
PAPeter Adewuyi
Peter Adewuyi
MBMustapha Bittaye
Mustapha Bittaye
This report describes acute kidney injury linked to imported pediatric medications among children in Gambia.

6 November 2025 in PLOS Global Public Health
Verified
Journal Article
Open access
PDF file
PBParsa Bastani
Parsa Bastani
ELEdgar Bailey Leonardo
Edgar Bailey Leonardo
JFJose Carlos Monzon Fuentes
Jose Carlos Monzon Fuentes
CPCesár Conde Pereira
Cesár Conde Pereira
EGEmily Zielinski Gutierrez
Emily Zielinski Gutierrez
PSParminder S Suchdev
Parminder S Suchdev
In February 2023, H5N1 was identified in 11 wild pelicans in Izabal, Guatemala. These were the first known cases of H5N1 in the country. This study assessed the timeliness of the response to this One Health event using the “7-1-7” benchmarks, which propose the following metrics: detection within seven days, notification within one day, and completion of early response within seven days. Open-ended interviews were conducted in September 2023 with nine key informants from the Ministry of Agriculture, Livestock, and Food (MAGA) and the Ministry of Health and Social Assistance (MSPAS) who were directly involved in the response. Participants included epidemiologists, laboratory analysts, and other relevant personnel. Interviews were analyzed using UNICEF’s “Human-Centered Design 4 Health” approach to qualitative fieldwork. Detection and notification were completed in one day, while early response was completed in 34 days. Key enablers of the response included interregional notification and cooperation, availability of earmarked emergency funds, event-based surveillance, and support from laboratories across public and private sectors. Reported bottlenecks included limited national laboratory testing capacity, challenges in inter-agency and intra-agency communication, workforce constraints, and equipment shortages. This outbreak response met the detection and notification criteria but did not achieve the 7-day target for completing early response activities. As one of the few qualitative studies examining avian influenza response in Central America, these findings highlight how strengthening a One Health approach, particularly in communication, workforce, and laboratory capacity, could enhance preparedness for future outbreaks.


6 February 2020 in Journal of Substance Use
Verified
Journal Article
Closed access
MTMeghdad Talebizadeh
Meghdad Talebizadeh
FLFahimeh Fathali Lavasani
Fahimeh Fathali Lavasani
PBParsa Bastani
Parsa Bastani
ANAlireza Noroozi
Alireza Noroozi
Background: Cue exposure therapy (CET) is a behavioral approach for treating substance use disorder that due to lack of evidence, its efficacy has been matter of debate over the past two decades. We designed a randomized controlled trial (RCT) to investigate efficacy of adding CET to treatment as usual (TAU) as compare to TAU for stimulants (methamphetamine) use disorder. Methods: In this RCT, 40 patients with MA use disorder (MUD) who receive treatment from an outpatient clinic are randomly assigned to intervention (CET+TAU) or control (TAU) groups. The CET consisted of 10 weekly individual sessions providing exposure to MA-related cues. The TAU consisted of biweekly individual sessions of cognitive and behavioral treatment that aimed to help patients achieve initial abstinence and relapse prevention. The primary outcome of the study is percent of weekly negative urine tests. Secondary outcomes include severity of addiction, craving, depression, anxiety, stress, self-efficacy, and quality of life. Conclusion: There is no controlled data determining the CET efficacy of MUD treatment. The issues around development of CET for people with MUD and design of the study have been discussed in this study protocol.